Introduction {#Sec1}
============

The ubiquitin-proteasome system (UPS) is the major proteolytic system in the cytosol and nucleus of all eukaryotic cells (reviewed in Weissman et al. [@CR118]). Most of our initial understanding of this pathway comes from biochemical approaches and genetic studies in yeast (reviewed in Weissman et al. [@CR118]). Knowledge about the physiological roles of the UPS in mammalian cells was quite slow until cell-permeable proteasome inhibitors were developed (Palombella et al. [@CR81]; Tsubuki et al. [@CR110]). Proteasome inhibitors helped to demonstrate that 26S and 20S proteasomes contribute to the degradation of most short-lived and long-lived proteins that exhibit critical functions inside the cell such as transcription, apoptosis or cell cycle regulation, either through ubiquitin-dependent or ubiquitin-independent mechanisms (Glass and Gerner [@CR38]; Tanaka et al. [@CR106]). Consequently, UPS deregulation is linked to different human pathologies (Schwartz and Ciechanover [@CR95]). In this chapter, we will focus on UPS inhibitors used in the treatment of cancer.

Ubiquitin Proteasome-System {#Sec2}
---------------------------

The UPS is a complex system composed of multiple molecular machineries acting in a synchronous manner to maintain a dynamic equilibrium of their components. The UPS is often represented as two groups of separated molecular mechanisms: the first group comprises specific enzymes and cofactors acting to modify/de-modify protein substrates with a single member of the ubiquitin family; the second group of the UPS is the 26S proteasome, of approximately 2,000 kDa, which is responsible for the proteolysis of labelled substrates.

Protein Modification by Ubiquitin and Ubiquitin Family Members {#Sec3}
--------------------------------------------------------------

The ubiquitin family of protein modifiers, also known as Ubiquitin-like modifiers (UbLs), is composed of at least 15 members sharing a modest primary sequence identity with ubiquitin, but preserving its compact globular β-grasp fold (Hochstrasser [@CR45]). In mammalians, the family includes the small ubiquitin-like modifier (SUMO), the neuronal precursor cell-expressed, developmentally down-regulated protein-8 (NEDD8, also known as Rub1 in yeast), the ubiquitin cross-reactive protein (UCRP, alternatively named interferon-stimulated gene-15 ISG15), the ubiquitin-related modifier-1 (URM1), the human leukocyte antigen F-associated (FAT10), the Fau ubiquitin-like protein (FUB1), the MUB (membrane-anchored UBL), the ubiquitin fold-modifier-1 (UFM1), the ubiquitin-like protein-5 (UBL5, homologous to ubiquitin-1 \[Hub1\] in yeast), and the autophagy proteins ATG8 and ATG12.

Ubiquitin and all members of the ubiquitin family are attached to protein substrates through biochemical processes which are similar but implicate distinct sets of enzymes with the capacity to act on a limited number of reactions (Fig. [11.1](#Fig1){ref-type="fig"}). All protein modifiers of the ubiquitin family are generated through the proteolytical cleavage of higher molecular weight precursors that exposes the double glycine (GG) signature, typically found in this family, and which is required for their attachment to protein substrates (reviewed in Jentsch and Pyrowolakis [@CR51]). The attachment (or conjugation) of ubiquitin or UbL modifiers is mediated by a thiol-ester cascade of reactions that requires the action of three enzymes: an activating enzyme or E1 that will activate all molecules required for all reactions and a conjugating enzyme or E2 that, in most cases, will conjugate protein modifiers to their targets. Ubiquitin ligases or E3s are responsible for, or are required to achieve the conjugation of the modifier to its target protein (Fig. [11.1](#Fig1){ref-type="fig"}). The role that an E3 will exert depends on its capacity to form thiol-ester intermediates with protein modifiers. The ubiquitin ligases of the HECT family are typical examples of these active enzymes. Another category of E3 ligases contributes to bring together substrates and E2s in order to achieve protein conjugation without having any enzymatic activity. Among this category of E3s, we found the cullin-RING ligase (CRLs) composed of multiple subunits that will allow the specific recognition of a degradable substrate (e.g. after its phosphorylation). The contribution of E4 factors favouring chain extension has also been proposed (Hoppe [@CR47]). Chain formation is essential to drive distinct functions. While ubiquitin chain linkages K48 and K11 have been associated with degradation, K63 chains appear to connect signalling cascades, endocytic trafficking or DNA repair. The formation of hybrid chains containing ubiquitin and UbLs such as SUMO2/3 is also possible (Aillet et al. [@CR2]; Guzzo and Matunis [@CR42]; Kulathu and Komander [@CR59]) but a generic function of these chains has not been established. Deubiquitylating enzymes or DUBs recognize specific ubiquitin chains from target substrates through ubiquitin binding domains (UBDs) to know which chains should be cleaved (Eletr and Wilkinson [@CR28]). An equivalent reaction is achieved by SUMO-specific proteases (SUSPs) or NEDD8 specific protease (NEDP1), also known as Denedylase 1 (DEN1) (Hickey et al. [@CR44]). All isopeptidases show specificity for a modifier, however due to saturated in vitro assays, overexpression or certain stress conditions, cross-reactions have been reported thus making any conclusion on the exclusivity of these reactions difficult. Although the initial drug discovery strategies used enzymes recognizing protein substrates (E3s and isopeptidases) to develop new chemical inhibitors, nowadays all enzymes are considered as good candidates for drug development. Fig. 11.1**Available drugs in clinical trials to block the Ubiquitin-Proteasome System**. All members of the ubiquitin family are generated through a high molecular weight precursor that has to be cleaved by specific proteases to generate the mature form of each modifier. The covalent attachment of ubiquitin is mediated by a thiol-ester cascade of reactions involving at least three enzymes: an activating enzyme (AE) or E1; a conjugating enzyme (CE) or E2; and a ligase (LE) or E3. Ubiquitin-like proteins such as SUMO or NEDD8 have their own set of enzymes. Demodifying enzymes such as DUBs, SUSPs or NEDP1 participate in a proofreading mechanism. Multiple chain types can be formed and the composition of the chains is essential to drive distinct functions, including proteolysis by the 26S proteasome

Proteasomes {#Sec4}
-----------

The 26S proteasome is a multi-subunit complex formed by a barrel-shaped proteolytic core, the 20S core particle, and one or two regulatory 19S particles flanking the ends of the core to regulate the entry of proteins targeted for degradation (Fig. [11.1](#Fig1){ref-type="fig"}) (Bedford et al. [@CR4]). The 20S core particles consist of four stacked heptameric ring structures that are themselves composed of two different types of subunits. The two outer rings are formed by seven alpha subunits (α1--α7) that allow the interaction with the 19S particle, while the inner rings are composed of seven beta subunits (β1--β7), three of which are responsible for the catalytic activity. The catalytic mechanism of these subunits is the same because they use the hydroxyl group of the N-terminal threonine of a mature β-subunit to perform the nucleophilic attack on the carbonyl carbon of a peptide bond (Borissenko and Groll [@CR7]; Kisselev and Goldberg [@CR54]; Kisselev et al. [@CR55]; Voges et al. [@CR114]). Each subunit reacts with specific substrates: β1 subunit possesses peptidyl-glutamyl peptide-hydrolyzing (PHGH) activity that cleaves after acid residues, β2 has trypsin-like activity that cleaves after basic residues and β5 subunit shows chymotrypsin-like activity that cleaves after hydrophobic residues. Site-directed mutagenesis studies of these catalytic residues in yeast showed that the most drastic changes occurred when β5 subunit is inactivated (Heinemeyer et al. [@CR43]).

The 19S is divided into two sub-particles, the base and the lid. The lid contains at least nine non-ATPase polypeptide chains (Rpn3, 5--9, 11, 12 and 15) that remove the polyubiquitin chains from the protein-substrates, while the base consists of four non-ATPase (Rpn1, Rpn2, and Rpn13) and six ATPase subunits (Rpt1--Rpt6) that interact directly with α-rings. These ATPases control the opening of the 20S gate that is normally locked until an unfolded substrate is recognized. Only the unfolding step involves ATP hydrolysis (Peth et al. [@CR84]).

Apart from the proteasome, an immuno-proteasome exists in immune cells where the 11S subunit, also known as PA28 or REG, replaces the 19S subunit. The 11S is dominantly expressed in hematopoietic cells in response to pro-inflammatory signals such as interferon gamma or cytokines, and is involved in antigen processing for subsequent presentation to the MHC-I on the cell surface, allowing the initiation of the immune cell response (Rock et al. [@CR94]; Tanaka and Kasahara [@CR105]). Furthermore, the immune-proteasome facilitates the clearance of protein aggregates to prevent cell death produced by IFN-induced oxidative stress, (Seifert et al. [@CR96]). All proteasome inhibitors currently used in clinical trials block the enzymatic activities of the proteasome. However, the next generation of proteasome inhibitors will block other mechanism such as gate opening or regulatory subunits.

Targeting Proteasomes {#Sec5}
=====================

The first proteasome inhibitors made available were synthesized to specifically block the proteasome's active sites and to understand its enzymatic mechanism. Peptide aldehydes such as MG-132 were used to develop analogues with enhanced potency, selectivity and stability. Surprisingly, several studies showed that proteasome inhibitors induced rapid and selective apoptosis in different cancer derived cell lines, leading to the idea that proteasome inhibitors could be drug candidates. This idea was confirmed by the fact that the proteasome inhibitor Bortezomib regressed tumour size of xenograft tumours and also decreased metastasis and blocked angiogenesis in patients with hematologic malignancies. Thus, Bortezomib was the first proteasome inhibitor approved by the Food and drug Association of the United States (FDA). Since its approval in 2003, it became the frontline treatment for MM, it has been accepted as second line treatment of MCL and it has also been included in hundreds of on-going clinical trials. In addition to Bortezomib, Carfilzomib, another proteasome inhibitor, has been approved for relapsed/refractory MM, and other proteasome inhibitors are in clinical and preclinical trials (Table [11.1](#Tab1){ref-type="table"}).Table 11.1Proteasome inhibitors in clinical trialsDrug nameCompanyMolecular targetFamily structureBinding typeAdms routeClinical statusDiseaseRefBortezomib (Velcade)TakedaProteasome β5 \> β1\> β2BoronateReversibleIVSCIPLaunchedCancer: Multiple myeloma, non-Hodgkin's lymphomaAdams et al. ([@CR1])McBride and Ryan ([@CR67])Frankland-Searby and Bhaumik ([@CR35])[www.clinicaltrials.gov](http://www.clinicaltrials.gov)Phase IICancer: B-cell lymphoma, Hodking's lymphoma, leukaemia chronic lymphocytic, leukaemia acute myelogenous, small cell lung, non-small cell lung, prostate, gastrointestinal, breast, renal, liver, head and neck, ovarian, colorectal, oesophageal, pancreatic, sarcoma, bladder, glioblastoma, tyroid, osteosarcoma, mesothelioma, myelodyplastic syndrome, waldenstrom macroglobulinemia, unspecific solid tumorOthers: Lupus, HCV, HIV, cytomegalovirus infections, thrombotic disordersPhase ICancer: Melanoma, testicular, endometrial, metastatic, medulloblastomaCarfilzomib (PR171)OnyxProteasome β5 \>\> β1, β2EpoxyketoneIrreversibleIVLaunchedCancer: Multiple MyelomaFrankland-Searby and Bhaumik ([@CR35])McBride and Ryan ([@CR67])Demo et al. ([@CR23])Xolalpa et al. ([@CR119])Pautasso et al. ([@CR83])[www.clinicaltrials.gov](http://www.clinicaltrials.gov)Phase IICancer: Non-Hodgkin's lymphoma, leukaemia chronic lymphocytic, small cell lung, non-small cell lung, renal, unspecified solidOthers: Cytomegalovirus infectionsPhase ICancer: Hodgkin's lymphoma, leukaemia acute lymphocytic, leukaemia acute myelogenousMLN9708 (Ixazomib)TakedaProteasome β5 \> β1 \> β2BoronateReversibleIVPhase IIICancer: Multiple myelomaFrankland-Searby and Bhaumik ([@CR35])McBride and Ryan ([@CR67])Kupperman et al. ([@CR60])Xolalpa et al. ([@CR119])[www.clinicaltrials.gov](http://www.clinicaltrials.gov)OralPhase IICancer: Non-Hodgkin's lymphoma, leukemia acute myelogenousPhase ICancer: Hodgkin's lymphoma, leukemia acute lymphocytic, leukemia chronic lymphocytic, waldenstrom's hypergammaglobulinaemia, non-small cell lung, colorectal, melanoma, renal, sarcoma, prostate, pancreatic, head and neck, endometrial, breast, gastric, esophageal, testicular, liver, thyroid, unspecified solidCEP-18770 (delanzomib)TevaProteasome β5 \> β1 \> β2BoronateReversibleIVPhase IICancer: Multiple myelomaXolalpa et al. ([@CR119])Piva et al. ([@CR85])Frankland-Searby and Bhaumik ([@CR35])[www.clinicaltrials.gov](http://www.clinicaltrials.gov)OralPhase ICancer: Non-Hodgkin's lymphoma, non-small cell lung, colorectal, head and neck, ovarian, renal, prostate, unspecified solidONX-0912 (oprozomib)OnixProteasome β5EpoxyketoneIrreversibleOralPhase IICancer: multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia chronic lymphocytic, leukemia chronic myelogenous, waldenstrom's hypergammaglobulinaemiaXolalpa et al. ([@CR119])Frankland-Searby and Bhaumik ([@CR35])Chauhan et al. ([@CR11])[www.clinicaltrials.gov](http://www.clinicaltrials.gov)Phase ICancer: non-small cell lung, liver, prostate melanoma, ovarian, renal, gastric, colonorectal, medulloblastoma, breast, sarcoma, unspecified solidNPI-0052 (marizomib)NereusProteasome β5 \> β2\> β1Β-lactoneIrreversibleIVPhase ICancer: Multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukaemia chronic lymphocytic, leukaemia acute lymphocytic, leukaemia acute myelogenous, non-small cell lung, sarcoma, pancreatic, melanoma, prostate, liver, ovarian, breast, renal, gastric, unspecified solidXolalpa et al. ([@CR119])Fenical et al. ([@CR33])McBride and Ryan ([@CR67])Frankland-Searby and Bhaumik ([@CR35])[www.clinicaltrials.gov](http://www.clinicaltrials.gov)OralSyrbactins, Pono PharmaPono PharmaProteasomeSyrbactinIrreversibleUnspecifiedPreclinicalCancer: Myeloma, unspecifiedGroll et al. ([@CR024])Proteasome inhibitor IkerChemIkerChemProteasomeUnspecifiedUnspecifiedUnspecifiedPreclinicalCancer: Haematological unspecified, solid unspecified<http://www.ikerchem.com/our_research.html>Peptide epoxyketones Onyx PharmaceuticalsOnyx PharmaceuticalsProteasomeEpoxyketoneUnspecifiedUnspecifiedPreclinicalImmunological: Inflammatory disease unspecified<http://www.onyx-pharm.com/>ONX-0914( PR-957)Onyx PharmaceuticalsInmunoproteasomeβ5i/LMP7EpoxyketoneIrreversibleUnspecifiedPreclinicalImmunological: Arthritis, rheumatoid, psoriasis, inflammatory bowel disease, lupus erythematosusVerbrugge et al. ([@CR023])Cancer: haematological, unspecifiedFV-162Fluorinov PharmaProteasome β5FluorineIrreversibleOralPreclinical (Phase I planned)Cancer: Myeloma, non-Hodgkin's lymphoma<http://www.fluorinovpharma.com/>BortezomibmicelleNanoCarrierProteasome β5 \> β1\> β2BoronateReversibleUnspecifiedPreclinicalCancer: unspecified<http://www.nanocarrier.co.jp/en/research/pipeline/index.html>Timosaponin AIII(BN-108)BionovoProteasomeSteroidal saponinUnspecifiedOralPreclinical (Phase I/II planned)Cancer: breastChun-Nam et al. ([@CR025])

Proteasome Inhibitors in Clinical Use {#Sec6}
-------------------------------------

The new generation of proteasome inhibitors always aims to increase potency, specificity and stability with good bioavailability and pharmacokinetics. Conventional proteasome inhibitors efficiently block at least one of the three proteasome active sites (β1, β2 and β5) either with covalent or non-covalent, reversible or irreversible binding. Most Inhibitors and drugs in clinical trials are mimetic peptides that interact directly with the active site thus blocking the nucleophilic attack of the hydroxyl group of the proteasome N-terminal threonine active sites (Kisselev and Goldberg [@CR54]; Orlowski and Kuhn [@CR80]). Proteasome inhibitors are often classified according to their functional group (Table [11.1](#Tab1){ref-type="table"}):***[Boronic acid peptides]{.ul}***: Peptide aldehyde analogues were synthetized substituting the aldehyde group for boronic acid (**Bortezomib**) (Adams et al. [@CR1]). Bortezomib is more potent, stable and interacts more specifically with the β5 subunit, forming tetrahedral intermediates with two extra hydrogen bonds that stabilize the covalent bond (Groll et al. [@CR41]). Bortezomib is a reversible inhibitor administrated intravenously with very low dissociation rate that behaves as an irreversible molecule. It has a dose limiting toxicity and produces multiple side effects in patients, including pain, fatigue, gastrointestinal, cardiovascular and pulmonary disorders, neutropenia, thrombocytopenia and peripheral neuropathy. Despite its potency and effectiveness, about 60 % of the treated patients develop resistance to Bortezomib after 1 year of treatment (Mujtaba et al. [@CR73]). The resistance mechanisms are still poorly understood but have a multifactorial basis (Xolalpa et al. [@CR119]).A second-generation of proteasome inhibitors, currently in clinical trials, include the boronic acid peptides **MLN2238**, **MLN9708** and **CEP**-**18770**. Unlike Bortezomib, these inhibitors reduce neuropathy. MLN2238 and its oral analogue MLN9708, are reversible inhibitors in phase III trials with stronger chymotrypsin-like activity inhibition in vivo and a faster dissociation rate, able to penetrate inside tissues (Kupperman et al. [@CR60]). The oral inhibitor CEP-18770 in phase I and II trials shows encouraging results for the treatment of haematologic and solid tumours (Piva et al. [@CR85]).***[Epoxyketone peptides]{.ul}***. These peptides are the most potent and specific proteasome inhibitors known. They form a morpholine adduct with the N-terminal threonine through a covalent and an irreversible bond (Groll et al. [@CR40]). **Carfilzomib** (Demo et al. [@CR23]) and **ONX**-**0912** (Chauhan et al. [@CR11]) belong to this class of inhibitors. They show a high chemical stability causing a stronger inhibition of the chymotrypsin-like proteasome activity than Bortezomib (Huber and Groll [@CR49]), and overcome the problem of resistance to Bortezomib. Due to their higher specificity, neurotoxicity is reduced (Molineaux [@CR72]) but other side effects still persist (Fostier et al. [@CR34]). Carfilzomib is currently used for relapsed and refractory multiple myeloma and the orally bioavailable ONX-0912 is included in phase I and II trials where it has shown an improved therapeutic window.β[-]{.ul} ***[lactones]{.ul}*** [:]{.ul} *Non*-*peptidic inhibitors* have also been developed to improve bioavailability. The compound derived from the marine microorganism *Salinispora tropica*, **Marizomib**, is a β-lactone inhibitor in phase I trials (Fenical et al. [@CR33]). Its β-lactone group reacts with the catalytic threonines of the proteasome active site forming an acyl-ester adduct and a tetrahydrofuran ring that stabilizes the binding leading to a highly potent, selective and orally bioactive proteasome inhibitor. Contrary to epoxyketones and peptide boronic acids, Marizomib inhibits the three activities of the proteasome irreversibly, in a stronger (more than 90 %) and longer-lasting way (Miller et al. [@CR71]). The use of marizomib results in adverse effects such as fatigue, nausea, vomiting and dyspnea.

Development of New Proteasome Inhibitors {#Sec7}
----------------------------------------

A second generation of proteasome inhibitors is being designed to specifically inhibit a subunit of interest, to reduce toxicity in normal cells and increase apoptosis in tumour cells (Parlati et al. [@CR82]). This is the case of **FV**-**162** that shows a better inhibition of chymotrypsin-like with an improved safety profile compared to carfilzomib, and the epoxyketone ONX 0914. ONX 0914 is a potent drug orally bioavailable for the immunoproteasome and has been developed for the treatment of autoimmune disorders.

Moreover, natural products and non-covalent proteasome inhibitors are also being developed to reduce side effects. **Timosaponin AIII** is an example of a natural product in preclinical development whose phases I/II in breast cancer are under preparation. **Withaferin A** and **gambonic acid** are other natural inhibitors, which have been approved by the Chinese FDA for cancer clinical trials.

To avoid resistance to proteasome inhibitors, and to limit the off-target effects, the development of compounds acting in a non-competitive way that do not directly interact with the active catalytic β subunit's site, has been considered. These compounds could potentially be used in combination with Bortezomib to improve clinical outcomes. For example, Rapamicin and **PR**-**39** are compounds that bind to the α7 subunits, thereby producing a disruption in the interaction between 20S and 19S regulatory subunits that blocks the entry of the substrate (Gaczynska et al. [@CR36]). **5**-**amino**-**8**-**hydroxyquinoline** also interacts with the α-subunits inside the proteolytic chamber; while being cytotoxic for myeloma and leukemia cells in vitro, it has also been shown to decrease tumour size in xenograft tumour growth in vivo (Li et al. [@CR66]), and overcomes resistance to Bortezomib in cultured cell lines.

Cellular Effects of Proteasome Inhibitors {#Sec8}
-----------------------------------------

Proteasome inhibitors are successful in cancer cells with high proliferative rates. Although all mechanisms are not fully understood, it seems that they block the degradation of proapoptotic proteins and cell cycle regulators (Fig. [11.2](#Fig2){ref-type="fig"}). Among them, the tumor suppressors retinoblastome (Rb), p53 and the cyclin-dependent kinase inhibitors (CDKIs), such as p21Cip1, p27Kip1 and p57Kip2 are degraded by the proteasome (Frankland-Searby and Bhaumik [@CR35]; Rastogi and Mishra [@CR87]; Vlachostergios et al. [@CR113]). Regulators of the intrinsic apoptotic pathway are also controlled by the proteasome, including members of the Bcl-2 protein family (p53-target-genes) such as the proapoptotic proteins Bax, Bid, Noxa or Bad, and anti-apoptotic members such as Bcl-XL and Bcl-2. Bortezomib treatment increases the expression of proapoptotic members such as Bax, Smac and Noxa while anti-apoptotic proteins like Bcl-2 and IAPs are down-regulated, thus favoring apoptosis in tumor cells (Crawford and Nahta [@CR20]). Fig. 11.2**Cellular effects of proteasome inhibition**. Inhibition of the proteasome stabilizes and activates critical factors that control several apoptotic pathways in cancerous cells. Most pathways affected are involved in cell cycle control, cell proliferation, oncogenic activity, apoptosis, tumour suppressor functions and includes other multiple regulatory proteins (see main text)

The mechanism to induce apoptosis of each proteasome inhibitor seems to be different, thus some combinations result in synergies. For example, Carfilzomib and Marizomib induce apoptosis mediated by caspase 8 and 9 better than Bortezomib, which is more dependent on Bax and Bak mitochondrion-mediated cell death (Kuhn et al. [@CR58]; Miller et al. [@CR70]).

The inhibition of NFκB by Bortezomib seems to have an important role in this drug's mechanism of action, although it cannot explain all the anticancer effects (Fig. [11.2](#Fig2){ref-type="fig"}). NF-κB-mediated transcription plays a crucial role in tumorigenesis by controlling among others the immune and inflammatory responses; apoptosis suppression (by inducing anti-apoptotic IAPs and BCL-XL proteins); angiogenesis promotion (by inducing vascular endothelial growth factor VEGF and COX2); favouring cell proliferation (by increasing cyclin D) and increasing cell migration (by inducing metallo-proteases) (Roccaro et al. [@CR93]). Furthermore, constitutive expression of NF-κB has been related with resistance against radiation and chemotherapy in various types of cancer (Sunwoo et al. [@CR104]).

Disruption of the proteasome activity also leads to the aggregation of unfolded proteins, thereby producing ER stress. An extensive protein production and secretion has been found in different types of cancer, becoming more sensitive to ER stress (Hoeller and Dikic [@CR46]). ER stress leads to up-regulation of the endoribonuclease/kinase IRE1a and the transcription factors ATF3&4 that will increase transcriptional activation of the pro-apoptotic Noxa (Armstrong et al. [@CR3]). Autophagy is also induced by ER stress as a resistance mechanism to escape cell death through the eIF2α induced pathway, the activation of HDAC6, the IRE1-JNK pathway, by proteasomal stabilization of ATF4, the inhibition of mTOR, and by the reduced proteasomal degradation of LC3 (Belloni et al. [@CR6]). The activation of p38 MAPK and c-Jun N-terminal kinases has been also reported after proteasome inhibition. This leads to 14-3-3 phosphorylation and consequently to cytochrome c release. The generation of reactive oxygen species (ROS) after the treatment with proteasome inhibitors results in the expression of apoptosis-related proteins (Fan et al. [@CR31]). ROS are responsible for DNA damage and proteasome plays a crucial role in DNA repair through the activation of p53 and other pathways.

Experience with Clinical Trials {#Sec9}
-------------------------------

Bortezomib has shown promising activity and a durable response as a single agent in relapsed or refractory MCL and MM patients (Table [11.1](#Tab1){ref-type="table"}). Trials in Phase I demonstrated an effective plateau at 65--70 % proteasome inhibition with fair tolerance levels. In phase II, 35 % of patients with refractory MM and 46.5 % of patients with pre-treated MCL responded to Bortezomib, therefore the FDA initially approved it for relapsed/refractory MM in 2003, and subsequently for relapsed/refractory MCL in 2006 (Kane et al. [@CR52]). Moreover, survival rates of refractory MM patients using Bortezomib in phase III trials exceeded the response rates for patients treated with the previous drug choice Dexamethasone, resulting in Bortezomib being approved as a first-line therapy in 2008 (Richardson et al. [@CR92]). However the refractory response to Bortezomib depends on the tumour cell type. Pancreatic, prostate and non-small lung tumour cells are sensitive while diffuse large B cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and some solid tumours such as sarcoma, renal cell carcinoma and glioma only provide slight and short responses (Frankland-Searby and Bhaumik [@CR35]).

To overcome Bortezomib resistance, numerous combinations with chemotherapeutic agents, immunomodulators and/or other proteasome inhibitors are under investigation. In 2007, the FDA approved the use of a Bortezomib/Doxorubicin combination since it was better than the use of single compounds in phase III trials. Combinations with Doxorubicin/Adriamycin (ADR), Thalidomide, Melphalan, Dexamethasone, Cyclophosphamide and Myriad have also been successful. The most active combination to date includes Bortezomib, Lenalidomide and Dexamethasone, where overall responses of 100 % were obtained in phase II. Early phase I and II clinical trials using combinations of Bortezomib with new immunomodulators, radio-immunotherapy, stem cell transplantation, monoclonal antibodies or chemotherapeutic agents have been promising. In addition, targeted therapies such as histone deacetylase inhibitors, Bcl-2 inhibitors, rapamycin inhibitors, multiple kinase inhibitors (Akt, PKC, CDK inhibitors, etc.) and heat shock protein inhibitors simultaneously used with Bortezomib also show encouraging results (McBride and Ryan [@CR67]).

**MLN9708** shows synergistic effects in association with Bortezomib, vorinostat, lenalodomide and dexamethasone, in refractory MM (phase III) and first line MM patients (phase I/II) (McBride and Ryan [@CR67]). Studies in phase I/II with **Carfilzomib** exhibit durable responses with acceptable toxicity in relapsed/refractory MM patients compared to Bortezomib and stem cell transplants, achieving a 24 % partial response in heavily pre-treated patients (McBride and Ryan [@CR67]; Pautasso et al. [@CR83]). Several phase II trials are currently on-going for haematological malignancies and solid tumours. Phase I/II trials with different compound combinations including Calfizomib/Thalidomide/Dexamethasone/Cyclosporamide are being also tested as a frontline treatment for MM, showing promising activity with high response rates in the first patients evaluated.

The last proteasome inhibitor that entered into phase I clinical trials was **Marizomib**, used alone or in combination with Dexamethasone for the treatment of different kinds of cancer (see Table [11.1](#Tab1){ref-type="table"}). In preclinical trials, Marizomib is also combined with Bortezomib, since different mechanisms of action have been suggested (McBride and Ryan [@CR67]).

Targeting NEDDylation {#Sec10}
=====================

Together with ubiquitin and SUMO, NEDD8 is among the most studied ubiquitin-like proteins (Fig. [11.1](#Fig1){ref-type="fig"}). The best known physiological substrates of NEDDylation are the cullins, which are structurally related proteins that function as molecular scaffolds of the cullin-RING family of E3 ubiquitin-ligases (CRLs). CRLs consist of a core cullin protein bound to a RING finger protein (Rbx1/2) and an interchangeable substrate-binding adaptor protein (Bedford et al. [@CR5]; Watson et al. [@CR117]). Rbx1 and Rbx2 in conjunction with E2 enzymes UBC12 and UBE2F, respectively, promote NEDDylation of cullins (Huang et al. [@CR48]). The archetypal CRLs, the so-called SCF ubiquitin ligases, contain CUL1, RBX1/2 and the adaptor protein Skp1. This core complex binds to one of the approximately 100 F-box proteins that are responsible for recruiting substrates (Bedford et al. [@CR5]). Cullin NEDDylation has been shown to increase the ubiquitylation activity of CRLs by promoting conformational changes that increase the binding of Rbx1 to ubiquitin E2s, which results in a reduction of the distance between E2 and the substrate recognition component; it may also lead to displacement of the negative regulatory protein, CAND1, that binds to non-NEDDylated cullin (Watson et al. [@CR117]). Specifically, the CRLs have been established to control the degradation of proteins with important biological roles, including cell cycle progression (p27, cyclin E, c-Myc), tumour suppression (p53), DNA damage (CDT1), stress responses (NRF-2, HIF-1α), and signal transduction (IκBα). In addition, other NEDD8-regulated substrates with key cancer-related functions are β-catenin, c-JUN, mTOR and MDM2. Interestingly, increasing evidence suggests that NEDD8-mediated protein turnover may be deregulated in malignant cells and could result in oncogenic transformation, disease progression, or impart a drug-resistant phenotype (Nawrocki et al. [@CR75]). For example, disruptions in the NEDD8 pathway lead breast cancer cells to acquire anti-estrogen resistance and expression of ER alpha (Fan et al. [@CR30]). It has also been shown that increased NEDD8 conjugation appeared to be essential for the enhancement of proliferation in several types of human carcinoma cells (Chairatvit and Ngamkitidechakul [@CR9]).

NEDDylation Inhibitors {#Sec11}
----------------------

Because many CRL substrates have tumour suppressor activity, preventing the degradation of these proteins could be an effective anticancer strategy that may also help to reduce toxicities resulting from global proteasomal inhibition (Nawrocki et al. [@CR75]). **MLN4924**, a potent and selective first-in-class small molecule inhibitor developed by Millennium Pharmaceuticals, was reported as a specific inhibitor of protein NEDDylation through the inactivation of the heterodimer APPBP1 (NAE1) and UBA3 (UBE1C), also known as the NEDD8 activating enzyme NAE (Soucy et al. [@CR100]; Wang et al. [@CR116]). MLN4924 is an adenosine sulphamate that forms a covalent adduct with NEDD8 when bound to the NAE active site and in this way inhibits the formation of UBC12-NEDD8 thioester. The MLN4924-NEDD8 adduct *mimics* the NEDD8-AMP in situ which is the first intermediate in the NAE reaction cycle, but cannot be enzymatically processed further (Brownell et al. [@CR8]; Nawrocki et al. [@CR75]). MLN4924 inhibits CRL activity and the stabilization of their substrates by blocking NAE, with subsequent implications in cancer cell growth and survival (Bedford et al. [@CR5]). In 2009, MLN4924 was first reported as a potent growth suppressor agent against a variety of cancer cells lines derived from solid tumours and haematological malignancies in both in vitro and in vivo xenograft models (Soucy et al. [@CR100]; Zhao et al. [@CR121]). During preclinical trials, tumour regression occurs after the action of different mechanisms depending on context and cell type. Induction of apoptosis is one of the reported effects mediated by MLN4924 in three different mechanisms mainly caused by the accumulation and stabilization of CRL substrates like: (1) CDT1, which trigger DNA re-replication and S phase arrest; (2) IκBα, that blocks NF-κB activation, and; (3) pro-apoptotic NOXA. In addition to apoptosis, MLN4924 also induces autophagy in a concentration- and time-dependent manner in multiple human cancer cell lines derived from carcinomas of breast, colon, liver, brain and cervix. Studies revealed that autophagy is mainly caused by inactivation of mTORC1, most likely mediated by accumulation of DEPTOR and HIF1α, followed by the activation of the HIF1-REDD1-TSC1 axis. Some studies have also shown that MLN4924 can induce irreversible senescence in multiple cancer cell lines in a p21-dependent manner. In SK-BR3 cells, p16 and p27 accumulation may also contribute to the MLN4924-induced senescence. Furthermore, MLN4924 has a potential sensitizer role in chemotherapy and radiation, involving the mechanistic accumulation of c-Jun, NOXA, CDT1, WEE1 or p21; it also affects the promotion of c-FLIP degradation, increasing the expression of Bcl-2-interacting killer (BIK), inactivating CRL3, as well as the suppression of FANCD2 monoubiquitylation and CHK1 phosphorylation, all of which results in a general increase in cellular sensitivity by enhancing DNA damage, oxidative stress, cell cycle arrest and finally apoptosis (Zhao et al. [@CR121]). Despite this promising optimal strategy to inhibit NAE pathway, recently it has been identified that cancer cells can develop resistance to MLN4924 treatment. Resistance has been linked to heterozygous mutations in two areas of NAEβ (UBA3), the ATP binding pocket at Alanine 171 and at various residues within or close to the NEDD8-binding cleft. A point mutation in residue A171T reduced affinity for both MLN4924 and ATP. Interestingly, such resistance has been effectively bypassed by using a compound with tighter binding properties for NAE. These findings provide critical clinical aspects with respect to patient selection and consolidate efforts for the development of next-generation NAE inhibitors in order to overcome emergent mutations (Milhollen et al. [@CR69]; Toth et al. [@CR108]). In fact, by using a virtual screening approach, a natural product, 6,6″-biapigenin, has been identified and proposed as a second inhibitor of NAE (Leung et al. [@CR64]). In 2012, a cyclometallated rhodium (III) complex was reported as the first metal complex to suppress the NEDDylation pathway via inhibition of NAE, which occupied the same binding pocket as MLN4924 (Zhong et al. [@CR122]).

Experience with Clinical Trials {#Sec12}
-------------------------------

In parallel with the promising results in preclinical models, MLN4924 has been included in clinical trials for cancer therapy since 2008 (see Table [11.2](#Tab2){ref-type="table"}). Up to now, there are a total of seven Phase I/II clinical trials for MLN4924 in patients with leukaemia, lymphoma, melanoma and several solid tumours. These trials were mainly designed to assess the safety, discomforts and risks of the inhibitor; to establish the maximum tolerated dose (MTD) that can be given to patients; to describe the pharmacokinetics (PK) parameters and pharmacodynamics (PD) effects; to evaluate disease response, and to study MLN4924 in combination with other standard treatments. In general, patients received escalating doses of MLN4924 that was administrated via intravenous infusion on different daily schedules. The pharmacokinetics of MLN4924 were measured in serial blood samples, bone marrow aspirates (BMAs), skin punch biopsies, or fine-needle tumour biopsies collected following drug dosing. The samples were analysed to measure MLN4924-NEDD8 covalent adduct and the expression of CRL substrates, such as CDT1, NRF2, and phospho-IκBα, as the biomarkers to indicate NAE inhibition in peripheral and tumour tissue (Zhao et al. [@CR121]). The PK profiles were similar following dosing on different days, suggesting no apparent accumulation of MLN4924 in plasma with an estimated half-life of 5--15 h. In general, most clinical trials carried out thus far have concluded that MLN4924 is well tolerated in the majority of the dosing schedules studied, with evidence of target inhibition and antitumoural activity which supports continued investigation of MLN4924, both alone and in combination strategies as potential treatment for a variety of human cancers (Nawrocki et al. [@CR75]; Zhao et al. [@CR121]).Table 11.2Clinical trials for MLN4924Disease typeClinical statusWith combinationMTDResponsesRefAdvanced Solid tumorsPhase IAloneWith dexamethasone (Dex)50 mg/m^2^ in Schedule A (days 1-5);Stable diseaseClinicaltrials.gov Identifier: NCT00677170Kauh et al. 2011. J Clin Oncol (ASCO Annual Meeting Abstracts) 29 (suppl; abstr 3013)67 mg/m^2^ in Schedule B (days 1, 3 and 5 + Dex);50 mg/m^2^ in Schedule C (days 1, 3 and 5)Relapsed and/or refractory Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma and Multiple MyelomaPhase IAlone110 mg/m^2^ in Schedule A (days 1, 2, 8 and 9)3 partial response and stable diseaseClinicaltrials.gov Identifier: NCT00722488(Nawrocki et al. [@CR75])Shah et al. 2010. Blood (ASH Annual Meeting Abstracts) 116: abstract 2801Harvey et al. 2012 (17th Congress of European Hematology Association) abstract 1060TrialTroveID-170665Not reported for Schedule B (days 1,4, 8 and 11) and Schedule C (days 1 and 8)196 mg/m^2^ (twice-weekly schedule of days 1, 4, 8 and 11)Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic SyndromesPhase IAloneWith azacitidine59 mg/m^2^ (days 1, 3 and 5)4 complete responsesClinicaltrials.gov Identifier: NCT00911066Swords et al. Blood (ASH Annual Meeting Abstracts) 116: abstract 658Nawrocki et al. ([@CR75])Zhao et al. ([@CR121])Metastatic MelanomaPhase IAloneHas not been defined1 partial response and 9 stable diseaseClinicaltrials.gov Identifier: NCT01011530Bhatia et al. 2011. J Clin Oncol (ASCO Annual Meeting Abstracts) 29 (suppl; abstr 8529)Large B-cell LymphomaPhase I/IIAloneWith standard EPOCH-R chemotherapyNot reportedNot reported (study was withdrawn before participants were enrolled)Clinicaltrials.gov Identifier: NCT01415765Zhao et al. ([@CR121])Acute Myeloid LeukemiaPhase IbAloneWith azacitidineTo be determinedNot reportedClinicaltrials.gov Identifier: NCT01814826Zhao et al. ([@CR121])Solid tumorsPhase IbWith docetaxelWith gemcitabineWith carboplatin + paclitaxelTo be determinedNot reportedClinicaltrials.gov Identifier: NCT01862328Zhao et al. ([@CR121])

Targeting DUBs {#Sec13}
==============

The human genome encodes nearly 100 DUBs in five major classes: 60 Ubiquitin-specific proteases (USPs), 16 Otubain-domain containing proteins (OTUs), 4 Machado-Joseph Domain (Josephin domain)-containing proteins (MJD), 4 ubiquitin C-terminal hydrolases (UCHs) and 8 Jab1/MPN domain-associated metalloisopeptidases (JAMM). USPs, OTUS, MJD and UCHs use an active site cysteine as a nucleophile to attack lysine-glycine isopeptide bonds within ubiquitylated proteins (Nijman et al. [@CR78]), whereas the fifth class of DUBs contains a JAMM zinc metalloproteinase domain (Cope and Deshaies [@CR19]). DUBs are generally expressed as active enzymes, rather than inactive precursors. However, certain DUBs require ubiquitin binding to obtain their active conformation and prevent their uncontrolled proteolytic activity. Structural data revealed that ubiquitin-binding by DUBs is accompanied by active site rearrangements, which are necessary to induce their hydrolytic activity (Edelmann et al. [@CR26]; Komander et al. [@CR56]). DUB activity is also regulated through the binding of scaffold and adaptor proteins (Ventii and Wilkinson [@CR112]), proteolytic cleavages, as well as post-translational modifications (Kessler and Edelmann [@CR53]).

DUBs as Therapeutic Targets {#Sec14}
---------------------------

Due to the implication of DUBs in the regulation of crucial signalling pathways such as p53 and NF-κB (Fig. [11.2](#Fig2){ref-type="fig"}), it is not surprising that their deregulation is involved in a growing number of diseases, including neurological disorders, viral infections and cancer. Indeed, some members of the DUBs family are known to contribute to neoplastic transformation, such as USP1 (in Fanconi anaemia), USP2 (in prostate cancer), DUB3 (in breast cancer), USP4 (in adenocarcinoma), USP7 (in prostate cancer and non-small-cell lung adenocarcinoma), USP9X (in both leukaemia and myelomas) and BRCC36 (in breast cancer) (Edelmann et al. [@CR27]; Hussain et al. [@CR50]). The genetic alteration of DUBs such as CYLD and USP6, has been associated with skin and bone marrow tumour progression, respectively. Finally, an alteration of expression of A20 (B-cell and T-cell lymphomas), USP10 (carcinomas) and BAP1 (brain, lung and testicular cancers) is observed in some cancers (Hussain et al. [@CR50]; Nicholson et al. [@CR77]; Sippl et al. [@CR98]).

The high degree of substrate specificity and the well defined catalytic pocket make DUBs druggable and amenable to screening with libraries of small molecules (Eletr and Wilkinson [@CR28]). Work carried out over the last few years has led to the identification of inhibitors with selective action against various USP targets, demonstrating the feasibility of selective targeting of DUBs. In general, the initial hits have been obtained by high throughput screening (HTS) of compound libraries, followed by further optimization using structure-activity relationships (Kramer et al. [@CR57]). Companies like Novartis, Progenra and Hybrigenics have patented compounds inhibiting distinct DUBs (see Table [11.3](#Tab3){ref-type="table"}). Some of them will be presented in the following section. However, to the best of our knowledge, only a few of them have, as yet, entered into clinical trials.Table 11.3Inhibitors of Deubiquitylating enzymes in clinical trialsDrug nameCompanyMolecular targetFamily structureBinding typeAdms routeClinical statusDisease typeRefPimozideJanssen PharmaceuticaUSP1DiphenylbutylpiperidineReversibleOralLaunchedTourette syndromeschizophreniaChen et al. ([@CR14])Phase IVMovement disordersGarcia-Santisteban et al ([@CR37]) and Zhang and Sidhu ([@CR026])Opler and Feinberg ([@CR79])Neifeld et al. ([@CR76])Phase IIDepression, bipolar disordersPhase IAnxietyPreclinicalBreast cancer, melanoma, non-small-cell lung carcinoma6MGGlaxoSmithKlinePLproUSP14ThiopurineReversibleOralLaunchedCancer: Non-Hodgkin's lymphoma, acute lymphatic leukaemiaChen et al. ([@CR13])Chou et al. ([@CR17])Sippl et al. ([@CR98])Other: Psoriatic activity, inflammatory Bowel diseasePhase IVCancer: Leukemia acute lymphocyticOther: Crohn's disease ulcerative colitis, influenza vaccines, respiratory infectionsPhase IIICancer: Non-Hodgkin's lymphoma,Other: HBV, hepatitis vaccinePhase IICancer: colorectal6TG7GlaxoSmithKlinePLproUSP14ThiopurineReversibleOralLaunchedCancer: acute lymphoblastic leukaemiaChen et al. ([@CR13])Chou et al. ([@CR17])Sippl et al. ([@CR98])Other: inflammatory bowel diseasePhase IVCancer: Leukemia acute lymphocytic, leukemia acute myelogenous, non-Hodgkin's lymphomaOther: Crohn's disease, ulcerative colitisPhase IIIMyelodysplastic syndrome, supportive carePhase IICancer: breast, glioblastomaP-5091ProgenraUSP7Tri-substituted thiopheneNSUnspecifiedPreclinicalMultiple Myeloma (MM) and other cancersChauhan et al. ([@CR12])P-022077GRL0617Purdue UniversityPLpro5-Amino-2-methyl-N-\[(R)-1-(1-naphthyl)ethyl\]benzamideIrreversibleUnspecifiedPreclinicalViral infectionRatia et al. ([@CR88])HBX-19, 818HybrigenicsUSP7Cyano-pyrazine derivativesIrreversibleUnspecifiedDiscoveryCancerReverdy et al. ([@CR89])HBX-28, 258HBX-41, 108HybrigenicsUSP7Cyano-indenopyrazineReversibleUnspecifiedDiscoveryCancerReverdy et al. ([@CR89])Zhang and. Sidhu ([@CR026])IU1Dan Finley's LaboratoryUSP141-\[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl\]-2-(1-pyrrolidinyl)-ethanoneReversibleUnspecifiedDiscoveryNeurodegenerative diseases, Virus infectionLee et al. ([@CR62])Nag and Finley ([@CR74])HBX 90,397HybrigenicsUSP8Cyano-pyrazine derivativesNSUnspecifiedDiscoveryCancerZhang and Sidhu ([@CR026])GW7647GlaxoSmithKlineUSP1Propanoic acidReversibleUnspecifiedDiscoveryCancerChen et al. ([@CR14])

DUBs Inhibitors {#Sec15}
---------------

Recently, a HTS approach led to the identification of two potent and selective reversible inhibitors of the enzymatic activity of the USP1/UAF1 complex, **pimozide** and **GW7646**. USP1, one of the best-characterized DUBs, is a regulator of several important steps in the DNA damage response, mainly in Fanconi anaemia (FA), an hereditary disorder characterized by congenital abnormalities, progressive bone marrow failure, hypersensitivity to DNA cross-linking agents, genomic instability and increased susceptibility to cancer (Li et al. [@CR65]; Reyes-Turcu et al. [@CR91]). USP1 is frequently overexpressed in tumours like cervical and gastric cancer, melanoma and sarcoma. Importantly, USP1 inhibitors act synergistically with the chemotherapy drug cisplatin to inhibit the proliferation of cisplatin-resistant non-small cell lung cancer (NSCLC) cells (Chen et al. [@CR14]; Garcia-Santisteban et al. [@CR37]).

One company, Hybrigenics, has developed a variety of different inhibitors of the USP family (Table [11.3](#Tab3){ref-type="table"}). For example, **HBX41**-**108** is a cyano-indenopyrazine derived small molecule compound which modulates the catalytic reaction of USP7 (Colland et al. [@CR18]). USP7, also known as herpes virus-associated USP (HAUSP), is critical in cancer progression because of its destabilizing effect on the tumour suppressor p53 (Cheon and Baek [@CR16]; Cummins and Vogelstein [@CR22]). However, USP7 can also modify other substrates such as claspin, FOXO4 and PTEN, suggesting that USP7 exerts both p53-dependent and -independent effects on the control of cell proliferation and apoptosis (Faustrup et al. [@CR32]; Song et al. [@CR99]; van der Horst et al. [@CR111]). HBX41-108 treatments stabilize p53, activate transcription of p53-target genes without inducing genotoxic stress, and inhibit cancer cell growth. Another compound more recently developed by Hybrigenics, **HBX19**-**818**, is a second-generation of irreversible USP7 inhibitors; it is more specific than HBX41-108, and is capable of regulating USP7 substrates in cancer cells and recapitulating the USP7 knockdown phenotype (Reverdy et al. [@CR89]). Recently, an independent screen performed by Progenra also identified compound **P005091**, and analogues such as **P045204** and **P022077**, as USP7 inhibitors capable of inducing apoptosis in multiple myeloma cells resistant to both conventional and Bortezomib therapies (Chauhan et al. [@CR12]).

Another HTS identified **IU1** as a selective and reversible small-molecule inhibitor of human USP14, which is, together with UCH37 and RPN11, a DUB associated with the proteasome. IU1 binds specifically to the activated form of USP14 and enhances the degradation of several proteins involved in neurodegenerative diseases (like Tau and ataxin-3), suggesting a potential strategy to reduce levels of misfolded and aggregated proteins in cells under proteotoxic stress (Lee et al. [@CR62]; Todi and Paulson [@CR107]).

Inhibitors of DUBs can also be used in antiviral drug development since viruses also encode for DUBs. For example, IU1, mentioned above, is also able to inhibit replication of Dengue virus (Nag and Finley [@CR74]). In the case of Severe Acute Respiratory Syndrome (SARS) caused by SARS-coronavirus, a DUB, called the papain-like protease (Plpro), blocks IRF3-dependent antiviral responses (Edelmann et al. [@CR27]; Mielech et al. [@CR68]). A non-covalent inhibitor of PLpro, **GRL0617**, has been synthesized. This inhibitor modifies the conformation of PLpro, inducing an inhibition of its catalytic activity, and selectively blocks SARS-Coronavirus viral replication without measurable cytotoxic effect (Ratia et al. [@CR88]). Looking for effective therapeutics against severe acute SARS, **6**-**mercaptopurine** (6MP) and **6**-**thioguanine** (6TG) were found to be specific inhibitors for PLpro. The potential use of 6MP and 6TG as cellular DUB inhibitors has been further studied. The best docking score and binding energy for 6MP and 6TG is against USP14 (Chen et al. [@CR13]; Chou et al. [@CR17]).

Experience with Clinical Trials {#Sec16}
-------------------------------

Recently, **Pimozide** and **GW7647** have been identified as potent inhibitors of USP1/UAF1 (Chen et al. [@CR14]). Pimozide is an antipsychotic drug also known for its neuroleptic property in the treatment of patients with schizophrenia (Opler and Feinberg [@CR79]), Tourette syndrome and resistant tics. In addition, pimozide inhibits the proliferation of human melanoma and breast cancer cells (Neifeld et al. [@CR76]; Strobl [@CR103]) and is able to reverse the chemo resistance of non-small cell lung cancer cells to the DNA cross-linker, cisplatin, further supporting USP1/UAF1 as a potential target for novel anticancer therapy (Chen et al. [@CR14]) (Table [11.3](#Tab3){ref-type="table"}).

**6MP6 and 6TG7** are antimetabolite antineoplastic agents with immunosuppressive properties, interfering with nucleic acid synthesis by inhibiting purine metabolism. These antimetabolites, also described as PLpro and potential USP14 inhibitors, are usually used in combination with other drugs, in the treatment of or in remission-maintenance programs for leukaemia. Several clinical trials have been established or are currently in progress using 6MP6 (166 trials listed in [www.clinicaltrial.gov](http://www.clinicaltrial.gov)) and 6TG7 (66 trials listed in [www.clinicaltrial.gov](http://www.clinicaltrial.gov)), in combination with other chemotherapeutic drugs, for the treatment of leukaemia, brain tumour, breast and ovarian cancer, as well as immune diseases.

Targeting Ubiquitin Ligases {#Sec17}
===========================

Several specific E3 ubiquitin ligases have been reported as deregulated or overexpressed in various diseases and cancers. Here, we will describe inhibitors of specific E3 ligases already in preclinical development or in phase I clinical trials (see Table [11.4](#Tab4){ref-type="table"}). However, due to the importance of the E3 ligase Mdm2 in the regulation of the tumour suppressor p53, many small molecule inhibitors of this protein-protein interaction were initially developed.Table 11.4Inhibitors Ubiquitin E3 ligases in clinical trialsDrug nameCompanyMolecular targetFamily structureBinding typeAdms routeClinical statusCancer typeRefMK-8242Merck & Cop53-mdm2 interactionNutlinsReversibleOralPhase ICancer: Leukaemia acute myelogenous, prostate, soft tissue sarcoma, unspecified solid[www.clinicaltrials.gov](http://www.clinicaltrials.gov)SAR-405838Ascenta Therapeuticsp53-Hdm2 interactionSpirooxindoleReversibleOralPhase ICancer: Non-Hodgkin's lymphoma, Hodgkin's lymphoma, soft tissue sarcoma, unspecified solidShen et al. ([@CR97])RO-5503781Hoffmann-La Rochep53-Hdm2 interactionNutlinsReversibleOralPhase ICancer: Leukaemia acute myelogenous, prostate, unspecified solidWang et al. ([@CR116])DS-3032Daiichi Sankyop53-mdm2 interactionImidazothiazoleUnspecifiedOralPhase ICancer: Non-Hodgkin's lymphoma, Hodgkin's lymphoma, melanoma, unspecified solid[www.clinicaltrials.gov](http://www.clinicaltrials.gov)CGM-097Novartisp53-Hdm2 interactionUnspecifiedUnspecifiedOralPhase ICancer: advanced solid tumours. Patients that do not respond to standard therapies[www.clinicaltrials.gov](http://www.clinicaltrials.gov)TL-32711 (birinapant)TetraLogic PharmaceuticalsIAPPropanamideUnspecifiedIVPhase IIICancer: colorectal[www.clinicaltrials.gov](http://www.clinicaltrials.gov)Myelodysplastic syndromePhase IICancer: Non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukaemia acute myelogenous, non small cell lung, small cell lung, melanoma, ovarian, pancreas, unspecified solidPhase ICancer: breastAT-406Ascenta TherapeuticsXIAP, IAP1 and IAP2CarboxamideUnspecifiedOralPhase IICancer: head and neck[www.clinicaltrials.gov](http://www.clinicaltrials.gov)Phase ICancer: Non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukaemia acute myelogenous, non-small cell lung, breast, ovarian, unspecified solidLCL-161NovartisIAPUnspecifiedUnspecifiedOralPhase IICancer: multiple myeloma, breast[www.clinicaltrials.gov](http://www.clinicaltrials.gov)Phase ICancer: pancreas, ovarian, colorectal, unspecified solidHGS-1029PharmascienceIAP2Hydrochloride saltUnspecifiedIVPhase ICancer: Non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukaemia acute lymphocytic, leukaemia chronic lymphocytic, non small cell lung, breast, colonorectal, head and neck, pancreas, prostate, unspecified solid[www.clinicaltrials.gov](http://www.clinicaltrials.gov)PO13222ProgenraMuRF1UnspecifiedReversibleUnspecifiedPreclinicalCancer Others: Prevention of muscle atrophy, AIDS, congestive heart disease, severe burnsEddins et al. ([@CR25])E6APCancerE6APUnspecifiedUnspecifiedUnspecifiedPreclinicalCancer: HPV-relatedDymalla et al. ([@CR24])InhibitorTherapeutics CRCAM-8735Amgenp53-Hdm2 interactionMorpholinoneUnspecifiedOralPreclinicalCancer unspecifiedGonzalez et al. ([@CR39])ATSP-7041Aileron TherapeuticsDualp53-Mdm2 p53-Mdmxα−helical peptidesUnspecifiedUnspecifiedPreclinical(Phase I planned)Cancer: breast, colonChang et al. ([@CR10])Hoffmann-La RocheLiposarcoma, melanoma, solid tumorsOthers: AML, CMLPXN-527Priaxonp53-Mdm2NutlinsReversibleOralPreclinicalCancer unspecifiedCheok et al. ([@CR15])PXN-523Nexus PharmainteractionSIAHCancer TherapeuticsSIAH protein interactionUnspecifiedUnspecifiedUnspecifiedPreclinicalCancer: pancreas, breast, ovarian, prostateStebbins et al. ([@CR102])inhibitorsAPN 401ApeironCbl-bNucleic acid: RNA interferenceUnspecifiedUnspecifiedPreclinicalCancer unspecifiedBachmaier et al. ([@CR028])BiologicsSynoviolin inhibitorProgenraSynoviolinUnspecifiedUnspecifiedUnspecifiedPreclinicalRheumatoid, Arthritis(RA)Yagishita et al ([@CR120])T-3256336TakedaIAPsPyrazine scaffoldsUnspecifiedOralPreclinicalCancer unspecified[www.clinicaltrials.gov](http://www.clinicaltrials.gov)IAP antagonistTakedaIAPsPyrazine scaffoldsUnspecifiedUnspecifiedPreclinicalCancer unspecified[www.clinicaltrials.gov](http://www.clinicaltrials.gov)IAP antagonistHoffmann-La RocheIAPsBenzoxazepinonUnspecifiedUnspecifiedPreclinicalCancer unspecified[www.clinicaltrials.gov](http://www.clinicaltrials.gov)AZ7732AstraZenecaIAPsBeta-alanine-derivedUnspecifiedUnspecifiedPreclinicalCancer unspecified[www.clinicaltrials.gov](http://www.clinicaltrials.gov)AT-IAPAstex PharmaceuticalsIAPsUnspecifiedUnspecifiedUnspecifiedPreclinicalCancer unspecified[www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Inhibitors of p53/Mdm2 {#Sec18}
----------------------

The tumour protein, p53, is involved in a broad range of critical pathways such as cell cycle, apoptosis, senescence, DNA repair, metabolism, development and innate immunity (Vousden and Prives [@CR115]). p53 monitors the integrity of the genome and is tightly regulated by different intracellular pathways, its main regulator being the ubiquitin E3 Hdm2 ligase (Mdm2 in mouse) that is involved in an auto-regulatory loop controlling p53 stability and activity. The transcription factor p53 has been found mutated and/or deregulated in about half of all known cancers (Soussi and Beroud [@CR101]). In other cases, p53 remains functional but abnormally retained by overexpressed or mutated Mdm2, or its homologue MdmX/Mdm4.

In 1996, the high-resolution crystal structure of Mdm2 with p53 was published (Kussie et al. [@CR61]) and more recently, the MdmX/p53 crystal structure was resolved (Popowicz et al. [@CR86]). From these studies, non-peptide small molecules inhibitors have been designed to specifically target the hydrophobic pocket including three trivial amino acids (Phe19, Trp23 and Leu26) common to both Mdm2 and MdmX. Hoffmann-La Roche has been the first company to develop one of the most potent Mdm2/p53 inhibitors, namely Nutlins. There are three generations of **Nutlins** (Nutlin-2; Nutlin-3a; RG-7112), with each generation aiming to improve the stability, affinity and bio-availability of the inhibitor. After optimization of Nutlin-3a, RG-7112 was the first Mdm2 inhibitor used in clinical trials to treat multiple human cancers (Tovar et al. [@CR109]). Other companies like Amgen developed a series of optimized compounds from the **piperidinone** class of compounds, obtaining **AM**-**8553** that efficiently inhibits tumour regression (Rew et al. [@CR90]). Since 2013, Amgen also developed the Mdm2 inhibitor, **AMG**-**8735**, containing a morpholinone core with a significant increase in both potency and metabolic stability compared to the piperidinone series. AMG-8735 emerges as an inhibitor with remarkable biochemical potency and pharmacokinetic properties (Gonzalez et al. [@CR39]) (Table [11.4](#Tab4){ref-type="table"}).

**ATSP**-**7041**, **developed by Aileron Therapeutics**, is the first highly potent and selective stapled α-helical peptide that functions as a dual inhibitor of Mdm2 and MdmX. ATSP-7041 binds to Mdm2 and MdmX with nanomolar affinities and restores p53 activity (Chang et al. [@CR10]). ATSP-7041 has a potential use for the treatment of solid tumours and cancers like AML, CML, breast cancer, liposarcoma, melanoma or colon cancer. Stapled α-helical peptides emerged as a promising new modality for a wide range of therapeutic targets. Based on Nutlin-3a (Roche), MI-219 (Ascenta) and TDP 222669 (Johnson&Johnson) structures, and using an NMR spectroscopy approach as an *in silico* compound-selection process, Priaxon AG developed two new classes of MDM2-inhibitors, **PXN**-**527** and **PXN-523** . These inhibitors have been tested in cellular cultures for inhibition of proliferation assays and are in preclinical trials (Cheok et al. [@CR15]).

Inhibitors of Other E3 Ubiquitin Ligases {#Sec19}
----------------------------------------

In addition to Mdm2/MdmX inhibitors, other inhibitors of ubiquitin E3 ligases are also in clinical trials. Progenra developed **PO13222**, a compound capable of specifically inhibiting the E3 ubiquitin ligase, MuRF1, a ligase associated with muscle wasting diseases. PO13222 specifically inhibits auto-ubiquitylation activity, without affecting ubiquitin E1 and E2 enzymes, resulting in the stabilization of muscle protein. This product is in preclinical development since 2012, the aim of which is to provide a novel therapeutic strategy to protect muscles from sarcopenia (aging) and atrophy associated with common diseases (such as cancer, AIDS and congestive heart disease) and severe burns (Eddins et al. [@CR25]) (Table [11.4](#Tab4){ref-type="table"}).

Progenra has also developed **Synoviolin**/**hrd1 inhibitors** for the treatment of rheumatoid arthritis (RA). Synoviolin is a RING E3 ubiquitin ligase implicated in the endoplasmic reticulum-associated degradation (ERAD) pathway. Synoviolin is highly expressed in rheumatoid synovial cells and possibly involved in the pathogenesis of RA. Using HTS, two classes of small molecules have been identified that efficiently inhibit synoviolin activity by inhibition of autoubiquitination enzymatic activity, thus blocking proliferation of synovial cells. This inhibitor has been in preclinical development since 2011 (Yagishita et al. [@CR120]).

High-risk oncogenic human papillomavirus (HPV) types (including HPV 16 and HPV 18) are associated with 99.7 % of all cervical cancers. The E6 and E7 oncoproteins are critical factors that maintain the malignant phenotype of HPV tumour cells. By using yeast two-hybrid screening, Cancer Therapeutics CRC developed linear short peptides that specifically bind with high affinity to the HPV16 E6 oncoprotein, affecting its interaction with the HECT-E3 ubiquitin ligase E6-AP (also known as UBE3A) that degrades p53. The restoration of intracellular p53 by using these short peptides is a new strategy for the treatment of HPV cancers. This E6AP inhibitor is in preclinical stage studies since 2012 (Dymalla et al. [@CR24]).

The E3 ubiquitin ligase Cbl-b is a key regulator of activation thresholds in mature lymphocytes, and of immunological tolerance and autoimmunity. Apeiron Biologics developed the specific Cbl-b ligase inhibitor, **APN**-**401**, that stimulates immune cells, providing a novel way to treat cancer more effectively. This compound is under preclinical development since 2012 ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

The SIAH ([S]{.ul}even [i]{.ul}n [A]{.ul}bsentia [H]{.ul}omologue) family of RING-E3 ubiquitin ligases regulates cellular events that are critical for cancer development and progression. Cancer Therapeutics developed a covalent peptides-based inhibitor (Cys-trapping moiety) to disrupt SIAH interactions with adaptor proteins, and thereby block cancer progression. These **small molecule SIAH inhibitors** are currently being tested in a preclinical phase for patients with breast, ovarian, prostate and pancreas cancers (Stebbins et al. [@CR102]).

Experience with Clinical Trials {#Sec20}
-------------------------------

The experience with ubiquitin E3 inhibitors in clinical trials is limited compared to proteasome inhibitors. Many of them are in phase I of clinical development and primary outcomes such as maximum tolerated dose, dose-limiting toxicities and safety are currently being evaluated. Subsequently, efficacy, pharmacokinetics and pharmacodynamics will be measured as secondary outcomes.

After the generation of the first inhibitor for Mdm2, RG-7112, Hoffmann-la Roche developed another Mdm2 inhibitor, **RO**-**5503781**, whose structure has not been published. This orally available inhibitor has been in phase I clinical trials since 2011 (NCT01462175), and is proposed to cancer patients with solid tumours and acute myelogenous advanced malignancies, except in the case of leukaemia. However, with respect to the latter, RO-5503781 has been included in another trial in combination with cytarabine, a chemotherapeutic agent used for treatment of leukaemia and non-Hodgkin lymphoma. A third trial is under consideration where RO5503781 will be used in association with cytarabine and anthracycline.

**SAR**-**405838** is a small analogue molecule of MI-888 (small molecule inhibitors of Mdm2), developed by Ascenta Therapeutics and Sanofi, that is currently in phase I of clinical trials since 2012, either alone (Clinical trial: NCT01985191) or in combination with Pimasertib (Clinical trial: NCT01636479). This oral drug may be used for patients with malignant neoplasm (Shen et al. [@CR97]).

**CGM097** is an oral HDM2/p53 inhibitor developed by Novartis for the treatment of cancer with advanced solid tumours, or for patients that have regressed despite standard therapy, or for whom no standard therapy exists. Cells have to exhibit wild type p53 to respond to this drug. CGM097 has been in phase I clinical trials since 2012 (NCT01760525).

Merck developed the **MK**-**8242** inhibitor that is included in phase I clinical trials for patients with advanced solid tumours when there is no other treatment available, or for recurrent acute myelogenous leukaemia and liposarcomas. Like RO5503781, MK-8242 is also being evaluated in phase I clinical trials in combination with cytarabine.

**DS3032b** is an oral Mdm2 inhibitor that has been developed by Daïchi Sankyo to treat patients with advanced solid tumours or lymphomas that exhibit mutated Mdm2 and a WT p53. The description of this molecule has not yet been published but it has already been included in phase I clinical trials (NCT01877382).

Conclusions and Perspectives {#Sec21}
============================

Even if the first pieces of the puzzle of this ATP-dependent pathway were discovered more than 30 years ago, every year new components and regulatory mechanisms controlling this system are being described. Despite this brief didactic view of the UPS classifying enzymes, cofactors and substrates, the system is a lot more complex than presented here, and there is still a distinct lack of knowledge with respect to its overall organization. For instance, it is well known that under certain circumstances several modifying/de-modifying enzymes can act on distinct members of the ubiquitin family (Leidecker et al. [@CR63]), that proteasome subunits can be substrates of ubiquitin and ubiquitin-like molecules (Cui et al. [@CR21]), or that the proteasome can also drive proteolysis in the absence of protein modification (Erales and Coffino [@CR29]). Although most of the functional outcomes of recent findings are not completely understood, it becomes clear that simply targeting a single enzyme-substrate pair will be difficult. However, this should not stop the use of these inhibitors to treat distinct pathologies, as has recently occurred with proteasome inhibitors that block multiple processes, since the discovery of drugs acting at different levels will also increase the chances of clinical success. Furthermore, the experience using combinations of different inhibitors is quite positive in cases where patients do not respond or are resistant to the current treatments. Although these combinatorial drug therapies might appear to be in contradiction with the initial aim of reducing undesirable side effects, it is possible that eventually they could be more effective. A compromise between efficacy and cytotoxicity should be better defined by pharmacodynamics and pharmacokinetic studies. Finally, although we described the use of UPS inhibitors to treat some cancers, many of them have also been used to treat quite diverse diseases such as cardiac, immune and neurodegenerative disorders. The use of chemical inhibitors will contribute to a better understanding of the multiple cellular pathways regulated by the UPS. More importantly, these inhibitors will open up new perspectives for the treatment of various diseases, as has been the case for Bortezomib/Velcade (reviewed by Xolalpa et al. [@CR119]).
